The proteasome controls a plethora of survival factors in all mammalian cells analyzed to date. Therefore, it is puzzling that proteasome inhibitors such as bortezomib can display a preferential toxicity toward malignant cells. In fact, proteasome inhibitors have the salient feature of promoting a dramatic induction of the proapoptotic protein NOXA in a tumor cell-restricted manner. However, the molecular determinants that control this specific regulation of NOXA are unknown. Here, we show that the induction of NOXA by bortezomib is directly dependent on the oncogene c-MYC. This requirement for c-MYC was found in a variety of tumor cell types, in marked contrast with dispensable roles of p53, HIF-1␣, and E2F-1 (classical proteasomal targets that can regulate NOXA mRNA under stress). Conserved MYC-binding sites identified at the NOXA promoter were validated by ChIP and reporter assays. Down-regulation of the endogenous levels of c-MYC abrogated the induction of NOXA in proteasomedefective tumor cells. Conversely, forced expression of c-MYC enabled normal cells to accumulate NOXA and subsequently activate cell death programs in response to proteasome blockage. c-MYC is itself a proteasomal target whose levels or function are invariably upregulated during tumor progression. Our data provide an unexpected function of c-MYC in the control of the apoptotic machinery, and reveal a long sought-after oncogenic event conferring sensitivity to proteasome inhibition. drug selectivity ͉ melanoma ͉ oncogenes ͉ apoptosis ͉ Bcl-2 family
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By using melanoma as an example of a highly chemoresistant tumor type, we and others have previously identified the protein NOXA as the first proapoptotic factor induced by bortezomib preferentially in cancer cells (4, 5) . For example, bortezomib promoted a 20-to 60-fold induction of NOXA in a large panel of melanoma cells, whereas levels in normal melanocytes remained barely detectable (4) (5) (6) (7) . Similar results were obtained with other proteasome inhibitors and in cells from breast cancer, small cell lung cancer, T cell leukemia, multiple myeloma, mantle-cell lymphoma, and squamous cell carcinoma (4, 5, (8) (9) (10) . This tumor cell-restricted induction of NOXA could not be recapitulated by standard chemotherapeutic agents such as doxorubicin, etoposide, or cisplatin, emphasizing a unique impact of bortezomib on the apoptotic machinery of tumor cells (4, 5) .
Human NOXA was initially identified as a phorbol esterresponsive gene (11) . However, the role of this protein in apoptosis became apparent when the murine homologue was identified as a p53 transcriptional target involved in the response to UV and a variety of DNA-damaging drugs (12) (13) (14) . The transcriptional factors HIF-1␣ and E2F-1 can also transactivate NOXA mRNA, suggesting a broad function in the response to cellular stress (15, 16) . In terms of functional domains, human NOXA contains one BH3 (Bcl-2 homology 3) domain, which has a high affinity for the antiapoptotic factor Mcl-1 (17) (18) (19) . MCL-1 is a ubiquitin target, and thus, it is up-regulated when the proteasome is inhibited (20) . NOXA is essential to counteract this high expression of MCL-1 and allow for the activation of the apoptotic machinery in response to bortezomib (7) .
The NOXA gene is not mutated or amplified during tumor development (21) . Therefore, a key question is why NOXA protein levels are induced by bortezomib preferentially in cancer cells but not in their normal counterparts. We and others have shown that the proteasome modulates not only the half-life of NOXA protein but also its mRNA levels (4, 5) . In this study, we address mechanisms controlling NOXA mRNA transcription to identify molecular determinants underlying the tumor cell selectivity of proteasome inhibitors. Unexpectedly, neither p53, HIF-1␣, nor E2F-1 were found to be essential for the proteasomal regulation of NOXA. Instead, we identify the oncogene c-MYC as a direct modulator of NOXA mRNA, and essential for the tumor cellselective regulation of NOXA by the proteasome. This study unveils an unexpected mechanism of regulation of the apoptotic machinery by c-MYC and underscores a strategy to exploit the altered genetic background of tumor cells for a specific induction of cell death.
Results
The Induction of NOXA by Bortezomib Is Dependent on New mRNA Synthesis. Bortezomib can induce NOXA protein and mRNA levels (4, 5) . However, the relative contribution of these two levels of regulation to the ultimate expression of NOXA is unclear (i.e., transcription de novo may be dispensable if a preexisting pool of NOXA protein is stabilized). To address this question, we first focused on the melanoma cell lines SK-Mel-19 and SK-Mel-103, as two representative examples of tumor cells that are highly responsive to bortezomib [see supporting information (SI) Fig. 6A ]. Human melanocytes were also used as a control for normal cells in which bortezomib fails to promote the accumulation of NOXA, despite an efficient inactivation of the proteasome (SI Fig. 6A ). By using this time course as a reference, cells were treated with bortezomib in the presence or absence of actinomycin D (Act D), a classical transcriptional inhibitor. As shown in SI Fig. 6B , low doses of Act D (not toxic for melanoma cells) were found to inhibit bortezomib-driven expression of NOXA by 90%. Therefore, these results emphasize a key role of de novo NOXA mRNA transcription in the response of cancer cells to bortezomib.
p53, HIF-1a, and E2F-1 Are Not Essential Modulators of BortezomibDriven NOXA Accumulation. The human NOXA promoter contains a p53 binding site and a hypoxia response element (HRE) at positions Ϫ195 and Ϫ1110, respectively, from the transcriptional starting site (ENSG00000141682) (Fig. 1A) . The impact of E2F-1 on human NOXA has not been addressed, but the E2F-1 binding site GTTCCCGG at position Ϫ48 in the mouse noxa promoter (ENSMUSG00000024521) can be found at nucleotide ϩ130 in the human NOXA sequence (Fig. 1 A) .
NOXA can be induced by bortezomib in a variety of tumor cell lines with defective p53 signaling (see SI Fig. 7A) . Moreover, a variety of clinical studies indicate that bortezomib can block tumor growth in a p53-independent manner (2, 22) . However, cooperative effects between p53 and bortezomib have been described in refs. 9 and 23. Therefore, it is conceivable that, although p53 is not strictly required for transcription of NOXA mRNA, it can still contribute as a cofactor to the accumulation of NOXA protein in bortezomibtreated cells. However, abrogation of p53 expression by short interfering RNAs (shRNAs) had no impact on the induction of NOXA and subsequent induction of cell death by bortezomib (SI Fig. 7 B and C) .
Next, we analyzed the relative expression of HIF-1␣ and E2F-1 at different time points after bortezomib treatment of melanocytes and a panel of 13 melanoma cell lines (to account for intraspecimen variability). Surprisingly, no obvious correlation was found between NOXA and HIF-1␣ or E2F-1 across cell lines (Fig. 1B) . Importantly, down-regulating the endogenous levels of HIF-1␣ with highly efficient shRNAs ( Fig. 2 A and B) or increasing HIF-1␣ levels by placing cells in hypoxia (SI Fig. 8A , right image), failed to alter the induction of NOXA by bortezomib in melanoma cells. Hypoxia was also not sufficient to allow for NOXA accumulation in bortezomib-treated melanocytes (SI Fig. 8A , left image).
E2F-1 was also found to be dispensable for the induction of NOXA by bortezomib. Two independent pools of short interfering RNA duplexes targeting a total of six different sites in the NOXA mRNA (Fig. 2C) were unable significantly affect the up-regulation of NOXA by bortezomib in melanoma cells, although the proteasome was efficiently inhibited (Fig. 2D) . Conversely, melanocytes could not be sensitized to bortezomib-driven NOXA induction, even on forced expression of E2F-1 (SI Fig. 8 B and C) . large set of consensus binding sites for known transcriptional factors (data not shown). Therefore, additional restriction criteria were needed to narrow the list of candidates for subsequent functional analyses. Because NOXA, as other Bcl-2 proteins, is highly conserved in mammalian species, we hypothesized that the transcriptional control may also be shared. Therefore, comparative analyses were extended to mouse and rat NOXA sequences. In addition, we focused on factors controlled by the proteasome and deregulated during tumor progression. This approach led to the identification of the oncoprotein c-MYC as a putative transcriptional modulator of NOXA mRNA. As depicted in Fig. 3A , four putative c-MYC binding sites (herein referred to BS I-IV), were found in the human NOXA promoter at positions Ϫ3773, Ϫ2246, ϩ87, and ϩ1897 ( Fig. 3 A  and B) . The BS III (CTCGCG) was found to be particularly intriguing. First, it is conserved among the three species analyzed. Second, analysis of the surrounding sequences indicated that this site mapped within a CpG island (Fig. 3A) , which is a frequent feature of c-MYC targets (24) . And, finally, this noncanonical MYC-binding site was shown to be recognized by c-MYC, in vitro and in vivo, as a part of the promoter of the c-MYC target GAPDH (25, 26) .
Endogenous c-MYC Interacts with NOXA Promoter in Vivo.
Well characterized antibodies against c-MYC and IgG (the latter as negative control) were used to define the binding of c-MYC to the NOXA promoter by ChIP. By using SK-Mel-19 as a representative example of an aggressive melanoma line, a Ͼ280-fold higher enrichment of amplified DNA was detected with the c-MYC antibody (Fig. 3C ). Of note, a similar effective binding was found for a well defined region of GAPDH promoter (26) containing the same MYC-binding site ( Fig. 3 B and C) . BS II and IV were bound less efficiently (i.e., the enrichment of precipitated material provided by the c-MYC antibody was 5.1-and 7.9-fold, respectively). No specific c-MYC binding was found at the more distant c-MYC BS I (Fig. 3C) . A similar pattern of recognition of the c-MYC binding sites was found in HeLa (see Fig. 3C , lower images), indicating that the binding of c-MYC to the NOXA promoter is not exclusive of melanoma cells.
Bortezomib-Driven and c-MYC-Dependent Transactivation of the NOXA Promoter. In cancer cells, c-MYC is regulated in part by posttranscriptional mechanisms (27, 28) . Therefore, we expected that the induction of NOXA by bortezomib would depend not on the basal levels of c-MYC mRNA, but on the ability of c-MYC to bind and recognize the NOXA promoter. In fact, c-MYC mRNA levels remained rather constant with treatment, whereas a 3-to 6-fold induction in the levels of c-MYC protein was observed in nearly all cell lines analyzed ( Fig. 4A and SI Fig. 9A ). Intriguingly, in seven of nine cases (SK-Mel-19, -28, -29, -103, -173, G-361, and UACC-62), NOXA mRNA and protein increased after progressive incubation with bortezomib, although there was not a strict linear correlation with c-MYC protein expression (see representative immunoblots in Fig. 4A and quantifications of immunoblots and RT-PCR analyses in SI Fig. 9 A and B) . Therefore, bortezomib may control not only the expression, but the activity of c-MYC at the NOXA promoter.
To further characterize the impact of the proteasome at the NOXA promoter, additional ChIP assays were performed in the absence and presence of bortezomib. As shown in SI Fig. 10 A and B, bortezomib increased by 2-to 3-fold the amount of c-MYC at the MYC-BS III (either by stabilizing its binding or by enhancing its effective concentration). This effect of bortezomib was not found at BS I (where no specific binding of c-MYC was detected). Notably, a comparable enrichment of acetylated histone H3 was also determined at the MYC-BS III (SI Fig. 10 A and B) , consistent with a transcriptional active site (29, 30) , as described for other c-MYC targets (31) . Mutagenizing the BS III, significantly abrogated the transcriptional activation by bortezomib at the NOXA promoter in luciferase-based reporter assays (SI Fig. 10C ). Taken together, these results identify NOXA as a direct target of c-MYC.
Depletion of c-MYC by RNA Interference Abrogates the Tumor CellSelective Induction of NOXA by Bortezomib. The role of the endogenous levels of c-MYC on the regulation of NOXA by bortezomib was analyzed with a previously validated shRNA (32) that has minor effects on cell viability at least during 6 days after infection (Fig. 4B) . By using this system, c-MYC levels were reduced by 80%. This inhibition of c-MYC abrogated the induction of NOXA by bortezomib without displaying unspecific effects on the proteolytic activity of the proteasome (Fig. 4C) . For example, the proteasome targets p53 and MCL-1 were induced with similar kinetics in melanoma cells expressing c-MYC-or control-shRNA (Fig. 4C) .
As we previously reported, bortezomib induces NOXA in a broad spectrum of tumor cell types. Therefore, we expected that the impact of c-MYC on the regulation of this protein would be tumor cell type independent. We showed that this was the case by using representative lines of melanoma (SK-Mel-19, -103, -147), breast cancer (MDA-MB-231), and cervical carcinoma (HeLa). In all these lines, c-MYC down-regulation caused a marked reduction (70-80%) in the amount of NOXA accumulated after bortezomib treatment (Fig. 4D and results not shown) . c-MYC Sensitizes Normal Melanocytes to Bortezomib-Induced NOXA Activation. Next, melanocytes were transduced with exogenous levels of c-MYC to determine whether this transcription factor is sufficient to enhance NOXA mRNA in primary cells. To this end, fresh preparations of normal human skin melanocytes were infected with lentiviruses coding for human c-MYC, at multiplicities of infection that allow for the expression of c-MYC within four to eight times the basal levels in tumor cells (Fig. 5A ). As shown in Fig.  5B , melanocytes overexpressing c-MYC showed a noticeable increase in NOXA mRNA, which was further induced (by 4-fold) after treatment with bortezomib. Moreover, melanocytes gained sensitivity to bortezomib in the presence of increased levels of c-MYC (Fig. 5 C and D) . Thus, c-MYC shifted the response of melanocytes from a G 2 /M cell cycle arrest to an effective killing, as measured by an increase in sub-G 1 DNA content (Fig. 5C) , and an enhanced amount of cell death after treatment (Fig. 5D ).
Functional Impact of c-MYC in Bortezomib-Induced Melanoma Cell
Death. Bortezomib is not a rapid death inducer, and at bioavailable doses, it is not sufficient to provide complete responses in mela- noma (4, 33) and other aggressive cancer types (22) . From a therapeutic point of view, it would be important if the occupancy of the NOXA promoter in tumor cells was not saturated (i.e., if increasing the levels of c-MYC could further enhance NOXA expression and, subsequently, cell death). This possibility was evaluated by transducing ectopic c-MYC in representative melanoma cells. Notably, exogenous c-MYC increased the sensitivity to bortezomib by reducing the amount of drug required for the induction of NOXA (Fig. 5E) . Importantly, ectopic c-MYC favored the response to low doses of bortezomib, increasing caspase processing (Fig. 5E) , and enhancing by 2-fold the extent of cell death (e.g., compare 85% of viable cells in control-treated populations with 30% when c-MYC is overexpressed) (Fig. 5F ). c-MYC was estimated to bind to 10-15% of transcriptionally active genes in the human genome (28) , and affect cell viability and apoptosis at multiple levels (34, 35) , which may act independently from NOXA. To define the relative contribution of this protein to c-MYC enhanced response to bortezomib, we blocked the endogenous expression of NOXA by a shRNA that we have previously validated (4). Interestingly, this NOXA shRNA reduced the c-MYC-driven killing by bortezomib to the levels of the control parental lines ( Fig. 5G ; P ϭ 0.009 in SK-Mel-19 and P ϭ 0.015 in SK-Mel-103; see figure legend for statistical analyses). Note that a complete inhibition of cell death was not expected because NOXA is not the sole driver of bortezomib-induced cell death, as previously reported in ref. 4 . Therefore, despite the multiple putative targets of c-MYC, the fact that blocking one single gene (NOXA) affects bortezomib-driven killing by c-MYC is highly significant. Together, these results support the potential of enhancing the intrinsic surplus of c-MYC in melanoma cells to activate NOXA, and favor cell death on proteasome inhibition. These data identify a role of c-MYC that may have translational implications for drug design.
Discussion
Complete and sustained proteasome blockage is incompatible with life (36) . Even transient inactivation of the proteasome can elicit a variety of changes in gene expression in normal and tumor cells (3) . How such a pleiotropic approach can provide a therapeutic index for clinical intervention is poorly understood (2). Here, we identified an unexpected interplay between the proteasome, the proapoptotic protein NOXA, and the oncogene c-MYC that provides a molecular explanation for the preferential selectivity of proteasome inhibitors toward tumor cells.
Requirement of c-MYC for the Dual Regulation of NOXA mRNA and
Protein by Proteasome Inhibition. Perhaps, one of the most unexpected results from this study is that HIF-1␣, E2F-1, or p53, all key proteasomal targets with binding sites at the NOXA promoter (12, 15, 16) , are largely dispensable in defining the ultimate expression of NOXA protein when the proteasome is blocked. Instead, here, we provide several lines of evidence that support a critical impact of c-MYC on the transcriptional control of NOXA. (i) By using computational analyses and ChIP methods, we identified and validated three c-MYC binding sites at the NOXA promoter. Of those, c-MYC BS III (located at position ϩ84, and within a CpG island) was found to be the most active. Our results also emphasize the differential impact of c-MYC on apoptotic modulators of the Bcl-2 family. Thus, c-MYC can induce NOXA mRNA, repress the antiapoptotic proteins Bcl-2 or Bcl-x L (37), activate the proapoptotic factor Bim EL (38) , or promote conformational changes in BAX (39) . Notably, of all these Bcl-2 family members, only NOXA is regulated in a tumor cell-selective manner (4, 5) . The fact that ectopic c-MYC expression can induce the accumulation of NOXA and shift the mode of action of bortezomib from cell cycle arrest to cell death, in otherwise poorly responsive normal melanocytes (Fig. 5 C and D) , provides a molecular explanation for the observation that c-MYC can sensitize primary cells to proteasome inhibition in vitro and in vivo (40) . The proteasome controls the half-life of the vast majority of cellular proteins (3) . Therefore, it would not be expected that bortezomib induced NOXA in malignant cells (even at the mRNA level), solely by stabilizing the endogenous levels of c-MYC. For example, proteasome inhibition can up-regulate various factors (e.g., ERK or JNK) that are frequently hyperactivated in tumor cells, and can modulate c-MYC function (27, 41) . Similarly, the transcriptional activity of c-MYC at the NOXA promoter can be favored by chromatin remodeling or modification proteins (including histone acetyl transferases), which can be modulated by c-MYC and by the proteasome (41) (42) (43) . The enrichment of histone H3 acetylation we found at the MYC BS III is consistent with these cooperating events. Still, the critical and preferential role of c-MYC for bortezomib-driven accumulation of NOXA, is illustrated by the dramatic inhibitory effect on NOXA levels on c-MYC shRNA (see model in SI Fig. 11 ). For some tumor cells, a strict dependency or ''addiction'' to specific oncogenes represents a point of vulnerability that can be exploited for rational drug design (44, 45) . This approach has been proven to be highly effective when the targeted oncogene is restricted to tumor cells and controls key events regulating cellular viability. Blocking c-MYC can compromise the proliferative capacity of normal cells (32, 47) . Therefore, instead of targeting c-MYC addiction, exploiting the ''surplus'' of this oncogene in tumor cells may provide an alternative therapeutic approach. For this strategy to succeed, the molecular circuitry of tumor cells should allow for an efficient, but tumor-restricted, induction of cell death. In the case of bortezomib, here we show that this selectivity can be provided by a preferential activation of NOXA in tumor cells. Importantly, ectopic expression studies suggest that the c-MYC-dependent control of NOXA is not saturated in tumor cells (Fig. 5) . Thus, it may be possible to rationally enhance the cytotoxic activity of bortezomib with drugs that further exploit the proapoptotic functions of this oncogene. This may be particularly important in the treatment of aggressive solid tumors, where bortezomib is not sufficient, as a single agent, for the induction of tumor regression.
In summary, this study has identified a mechanism of regulation of NOXA, defined a role of c-MYC in the activation of the apoptotic machinery of tumor cells, and provided a molecular framework that supports the notion of enhancing (instead of blocking) selective oncogenic signals to favor anticancer responses. Together, our results shed information into how a purportedly pleiotropic inactivation of the proteasome can be funneled to discrete oncogenes and their targets. An adroit exploitation of the inherently altered genetic makeup of tumor cells may provide a powerful strategy to kill malignant cells from ''within,'' while minimizing the risk of unwanted secondary toxicities.
Experimental Procedures
Cells. Normal melanocytes were isolated from neonatal foreskins, as previously described in ref. 4 , and maintained in media 254 supplemented with 0.2 mM CaCl 2 , 16 nM phorbol 12-myristate 13-acetate, and melanocyte growth factors (Cascade Biologics). Melanoma cell lines, MDA-MB-231, and HeLa were cultured in DMEM supplemented with 10% of FBS. Cells were incubated in 7% CO 2 , except for the low-oxygen content experiments, where cells were incubated in a hypoxia chamber (Biospherix), supplied with 95% N 2 and 5% CO 2 .
Reagents. Bortezomib (Velcade) was obtained from Millennium Pharmaceuticals. DMSO and ActD were from Sigma; and doxorubicin hydrochloride was from Fisher Scientific. The E2F-1 adenovirus has previously been described in ref. 48 . shRNAs against c-MYC or NOXA, and siRNAs to block E2F-1 expression are described in SI Materials and Methods.
Cell Viability Assays. The percentage of cell death at the indicated times and drug concentrations was estimated by standard trypan blue exclusion or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays. DNA content was estimated by propidium iodide-based staining and flow cytometry analyses (4). For simplicity, control samples treated only with solvent (0.1-0.05% DMSO) are indicated as NT (nontreated). Processing of apoptotic caspases was analyzed by monitoring the ratio of the full-length inactive proform to processed fragments generated on drug treatment and visualized by Western blotting.
Protein Immunoblots. Total cell lysates were obtained by Laemmli extraction. Protein samples were separated on 12% or 4-20% gradient SDS polyacrylamide gels and transferred to Immobilon-P membranes (Millipore). Protein levels were estimated by densitometry and normalized with respect to Tubulin or ␤-Actin, used as loading controls. Antibodies used for protein detection are described in SI Materials and Methods.
RNA Expression Analyses. The relative expression of NOXA, c-MYC, and CAD mRNA in normal and melanoma cells untreated or treated with bortezomib was determined by RT-PCR using the following primers: Noxa, 5Ј-ATG AAT GCA CCT TCA CAT TCC TCT (forward) and 5Ј-TCC AGC AGA GCT GGA AGT CGA GTG T (reverse); c-MYC, TCGGATTCTCTGCTCTCCTC (forward) and TCGGTTGTTGCTGATCTGTC (reverse); CAD, AG-ATGGAAGCGGCCATCAGGAAG (forward) and GGTG-GATCTGGAGCATGAGTGG (reverse). Expression levels were normalized to ␤-actin or GAPDH.
Promoter Assays. Direct binding of c-MYC to the NOXA promoter by ChIP was addressed by using the EZ-Chip kit from Millipore according to the manufacturer's recommendations. Briefly, 2 ϫ 10 7 SK-Mel-19 or HeLa cells were fixed in 1% formaldehyde. Chromatin was sheared to an average DNA size of 200-800 bp by sonication using Microson ultrasonic cell disruptor (10 times of 10-s pulses, 50% output). Sonicated chromatin was incubated overnight with 5 g of anti-c-MYC (N262; Santa Cruz), anti-acetylated Histone H3 (a gift from David Allis) or rabbit IgG (Upstate) antibodies. Immunoprecipitated DNA was de-cross-linked, purified by using columns from the kit and used in a PCR (GC-Rich PCR System; Roche) with the primers listed in SI Materials and Methods. PCR products were resolved on 1.5% agarose gel and stained with ethidium bromide. Generation of reporter assays containing wildtype and mutagenized c-MYC binding sites, and characterization of their transcriptional activity are described in SI Materials and Methods.
